4.3 Review

Genetic bases of hypertriglyceridemic phenotypes

期刊

CURRENT OPINION IN LIPIDOLOGY
卷 22, 期 4, 页码 247-253

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOL.0b013e3283471972

关键词

autosomal trait; complex trait; DNA sequencing; genome-wide association study; lipolysis

资金

  1. Canadian Institutes of Health Research (CIHR) [MOP-13430, MOP-79523, CTP-79853]
  2. University of Western Ontario
  3. Jacob J. Wolfe Distinguished Medical Research Chair at the University of Western Ontario
  4. Edith Schulich Vinet Canada Research Chair in Human Genetics
  5. Martha G. Blackburn Chair in Cardiovascular Research
  6. Heart and Stroke Foundation of Ontario [NA-6059, T-6018, PRG-4854]
  7. Pfizer
  8. Genome Canada through the Ontario Genomics Institute

向作者/读者索取更多资源

Purpose of review Hypertriglyceridemia (HTG) is a common diagnosis. Although secondary factors are important for clinical expression, susceptibility to HTG has a strong genetic component, which we review here. Recent findings Severe HTG in a few families follows Mendelian - typically autosomal recessive - inheritance of rare loss-of-function mutations in genes such as LPL, APOC2, APOA5, LMF1, and GPIHBP1. In contrast, common complex HTG results from the cumulative influence of small-effect variants (single nucleotide polymorphisms) in genes such as APOA5, GCKR, LPL, and APOB. Intensive resequencing of these four genes has also shown accumulated heterozygous rare variants in HTG patients. Together, more than 20% of the susceptibility to HTG is now accounted for by common and rare variants. Further, classical Fredrickson HTG phenotypes, which were once considered to be distinct based on biochemical features, have a shared genetic architecture. Summary Compared to other complex traits, genetic variants account for a high proportion of HTG diagnoses. By tallying the number of HTG risk alleles, it is possible to discriminate between individuals with HTG and normolipidemia, particularly in those with extreme scores. Future directions include finding the missing genetic component and determining whether genetic profiling can help with diagnosis or personalized treatment advice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Pathology

How reliable are polygenic risk scores for risk prediction in patients with heart disease?

Erin O. Jacob, Robert A. Hegele

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2023)

Article Pharmacology & Pharmacy

The longitudinal triglyceride phenotype in heterozygotes with LPL pathogenic variants

Shehan D. Perera, Jian Wang, Adam D. McIntyre, Jacqueline S. Dron, Robert A. Hegele, Cert Endo

Summary: In this study, the longitudinal triglyceride (TG) phenotype of individuals with heterozygous pathogenic LPL variants was evaluated. The results showed that TG levels varied widely among patients and within the same patient. Most patients exhibited mild-to-moderate and severe hypertriglyceridemia (HTG), and the severity likely depended on secondary factors.

JOURNAL OF CLINICAL LIPIDOLOGY (2023)

Editorial Material Cardiac & Cardiovascular Systems

'Keep on keeping on': persistence with lipid-lowering treatment in familial hypercholesterolaemia

Robert A. Hegele

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

The Impact of Low-Density Lipoprotein Equation Changes on Cholesterol Treatment in Canada

Pei Jun Zhao, Robert A. Hegele

Summary: The Canadian Society of Clinical Chemists has recommended adopting the more accurate Sampson/US NIH LDL-C equation for cardiovascular disease prevention. Based on the comparison of survey data, it is estimated that approximately 123,000 Canadians who are already taking cholesterol-lowering medications may need to intensify treatment due to the equation change.

CJC OPEN (2023)

Editorial Material Cardiac & Cardiovascular Systems

Apolipoprotein C-II: a new look at an old protein

Robert A. Hegele

EUROPEAN HEART JOURNAL (2023)

Review Cardiac & Cardiovascular Systems

2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

Marina Cuchel, Frederick J. Raal, Robert A. Hegele, Khalid Al-Rasadi, Marcello Arca, Maurizio Averna, Eric Bruckert, Tomas Freiberger, Daniel Gaudet, Mariko Harada-Shiba, Lisa C. Hudgins, Meral Kayikcioglu, Luis Masana, Klaus G. Parhofer, Jeanine E. Roeters van Lennep, Raul D. Santos, Erik S. G. Stroes, Gerald F. Watts, Albert Wiegman, Jane K. Stock, Lale S. Tokgoezoglu, Alberico L. Catapano, Kausik K. Ray

Summary: This 2023 statement provides updated clinical guidance for the management of homozygous familial hypercholesterolaemia (HoFH), including criteria for diagnosis, genetic testing interpretation, and treatment recommendations. The statement emphasizes the importance of considering both phenotype and genotype in the diagnosis of HoFH, with a LDL-C level >10 mmol/L (>400 mg/dL) being indicative of the condition. Combination therapy targeting LDL-C, including the use of novel therapies like proprotein convertase subtilisin/kexin type 9 inhibitors, is recommended to achieve LDL-C goals and reduce the need for lipoprotein apheresis. To improve HoFH care globally, the statement recommends the implementation of national screening programs, education to increase awareness, and management guidelines adapted to local healthcare systems.

EUROPEAN HEART JOURNAL (2023)

Review Pharmacology & Pharmacy

Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors

Catherine M. Spagnuolo, Robert A. Hegele

Summary: Mild-to-moderate hypertriglyceridemia (HTG) is associated with atherosclerotic cardiovascular disease (ASCVD) and elevated triglyceride (TG) levels. Apolipoprotein C-III (apo C-III) inhibition is a promising treatment approach for reducing TG levels and ASCVD risk. Biologic agents like volanesorsen, olezarsen, and ARO-APOC3 significantly reduce apo C-III and TG levels, but further study is needed on their impact on cardiovascular outcomes.

EXPERT OPINION ON PHARMACOTHERAPY (2023)

Article Cardiac & Cardiovascular Systems

International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia

Gerald F. Watts, Samuel S. Gidding, Robert A. Hegele, Frederick J. Raal, Amy C. Sturm, Laney K. Jones, Mitchell N. Sarkies, Khalid Al-Rasadi, Dirk J. Blom, Magdalena Daccord, Sarah D. de Ferranti, Emanuela Folco, Peter Libby, Pedro Mata, Hapizah M. Nawawi, Uma Ramaswami, Kausik K. Ray, Claudia Stefanutti, Shizuya Yamashita, Jing Pang, Gilbert R. Thompson, Raul D. Santos

Summary: Familial hypercholesterolaemia (FH) is a preventable cause of premature coronary artery disease and death. This guidance article from the International Atherosclerosis Society provides a comprehensive overview of FH care that includes recommendations on the detection and management of patients with FH, as well as strategies to maximize implementation.

NATURE REVIEWS CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Genetic Identification of Homozygous Familial Hypercholesterolemia by Long-Read Sequencing Among Patients With Clinically Diagnosed Heterozygous Familial Hypercholesterolemia

Ahsen Chaudhry, Mark Trinder, Kristin Vesely, Lubomira Cermakova, Linda Jackson, Jian Wang, Robert A. Hegele, Liam R. Brunham

Summary: A study found that approximately 0.9% of patients clinically diagnosed with heterozygous familial hypercholesterolemia (HeFH) actually had homozygous familial hypercholesterolemia (HoFH) based on genetic diagnosis. These patients had higher levels of low-density lipoprotein cholesterol and a higher prevalence of premature cardiovascular disease.

CIRCULATION-GENOMIC AND PRECISION MEDICINE (2023)

Review Cardiac & Cardiovascular Systems

Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management

Iulia Iatan, G. B. John Mancini, Eunice Yeoh, Robert A. Hegele

Summary: Statins are important for reducing the risk of atherosclerotic cardiovascular disease, but they are underutilized due to concerns about side effects. Statin-associated muscle symptoms are a common cause of intolerance and discontinuation, leading to increased risk of adverse cardiovascular outcomes.

EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2023)

Article Health Care Sciences & Services

Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada

Jean Lachaine, Jean -Nicolas Charron, Jean C. Gregoire, Robert A. Hegele, Lawrence A. Leiter

Summary: In a cost-utility analysis conducted from a Canadian healthcare payer perspective, icosapent ethyl (IPE) was found to be a cost-effective treatment option for statin-treated patients with elevated triglycerides. Compared to placebo, IPE was associated with a higher number of quality-adjusted life years (QALYs) and an incremental cost-effectiveness ratio (ICER) of $42,797/QALY gained. This analysis highlights the importance of IPE in reducing ischemic cardiovascular events in this patient population and its cost-effectiveness in Canada.

CLINICOECONOMICS AND OUTCOMES RESEARCH (2023)

Review Endocrinology & Metabolism

Low cholesterol states: clinical implications and management

Praneet K. K. Gill, Robert A. A. Hegele

Summary: This article reviews the causes and consequences of hypocholesterolemia resulting from genetic and non-genetic factors, and discusses therapeutic strategies inspired by genetic hypocholesterolemia.

EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2023)

Editorial Material Hematology

Academic-Industry Partnerships: Transparency, Potential Conflict of Interest, and Communicating State-of-the-Art Technologies

Ann Marie Schmidt, Mary G. Sorci-Thomas, Yabing Chen, Robert A. Hegele

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2023)

Editorial Material Cardiac & Cardiovascular Systems

Illuminating the full spectrum of APOE variation

Robert A. Hegele

ATHEROSCLEROSIS (2023)

Article Genetics & Heredity

Polygenic risk for triglyceride levels in the presence of a high impact rare variant

Shengjie Ying, Tracy Heung, Bhooma Thiruvahindrapuram, Worrawat Engchuan, Yue Yin, Christina Blagojevic, Zhaolei Zhang, Robert A. Hegele, Ryan K. C. Yuen, Anne S. Bassett

Summary: Elevated TG levels are modifiable risk factors for cardiovascular disease, and this study found that the TG-PRS, along with sex and BMI, were significant predictors of TG levels, especially in individuals with obesity. A combination of TG-PRS, sex, and BMI showed the greatest accuracy in predicting mild-moderate hypertriglyceridemia.

BMC MEDICAL GENOMICS (2023)

暂无数据